Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease

2021 ◽  
Author(s):  
Marguerite Conley ◽  
Katrina L. Campbell ◽  
Carmel M. Hawley ◽  
Nicole M. Lioufas ◽  
Grahame J. Elder ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Mineral Metabolism ◽  
Phosphate Intake ◽  
Dietary Phosphate

scholarly journals Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial

2012 ◽  
Vol 28 (1) ◽  
pp. 161-169 ◽  
Author(s):  
Mhairi Sigrist ◽  
Mila Tang ◽  
Monica Beaulieu ◽  
Gabriella Espino-Hernandez ◽  
Lee Er ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Randomized Trial ◽  
Mineral Metabolism ◽  
Phosphate Intake ◽  
Dietary Phosphate ◽  
Fgf 23

scholarly journals MP439RELATIONSHIP OF DIETARY PHOSPHATE INTAKE WITH SUBCLINICAL VASCULAR DAMAGE IN STAGE 3-5 NON-DIALYSIS CHRONIC KIDNEY DISEASE

2017 ◽  
Vol 32 (suppl_3) ◽  
pp. iii590-iii590
Author(s):  
Almirall Jaume ◽  
Betancourt Loreley ◽  
Martinez-Ocaña Juan Carlos ◽  
Ponz Esther ◽  
Luengo Marina ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Vascular Damage ◽  
Phosphate Intake ◽  
Dietary Phosphate ◽  
Subclinical Vascular Damage

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Sign in / Sign up

Export Citation Format

Share Document